503167-62-2

Upstream product

• 362489-59-6 1-tert-butyl 3-methyl 4-{[(1R)-1-phenylethyl]amino}-5,6-dihydropyridine-1,3(2H)-dicarboxylate 
• 503167-61-1 C₂₀H₂₈N₂O₄ 

Downstream Products

• 362489-61-0 1-tert-butyl 3-methyl (3S,4R)-4-aminopiperidine-1,3-dicarboxylate 
• 848002-73-3 (3R,4S)-4-Amino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 503167-63-3 4-aminopiperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 

Relevant academic research and scientific papers

Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors

β-Benzamido hydroxamic acids were discovered as potent TACE inhibitors. A computer model was constructed to help understanding the binding activities and guiding SAR study. SAR optimization led to the discovery of compound 30 which met all in vitro and in

Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase

This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.